STAT+: More signs that GLP-1s may help with peripheral artery disease

STAT PlusNewsletterThe Readout More signs that GLP-1s may help with peripheral artery disease Anthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenJuly 1, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I hope you’re all staying safe during this heat wave. Let’s get into the news today.Advertisement The need-to-know this morning Ipsen is buying Memo Therapeutics, the developer of an experimental antibody against a virus that can complicate kidney transplants, for about $228 million upfront. The deal, which expands Ipsen’s rare disease pipeline, comes just days after the French firm announced it was also acquiring Kartos Therapeutics, picking up its drug candidate for a rare blood cancer. Anthropic says it will begin developing drugs The AI giant Anthropic said yesterday that it will try to develop drugs on its own, with executives saying the company needs to get hands-on experience solving real scientific problems. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 1, 2026 STAT Plus: FDA approves Orca Bio’s T cell therapy for blood cancer patients Biotech July 1, 2026 STAT Plus: The biotech scorecard for the third quarter: 15 stock-moving events to watch Advertisement Biotech June 30, 2026 STAT Plus: AI company Anthropic announces it will begin developing drugs of its own Biotech June 30, 2026 STAT Plus: Anthropic releases Claude Science, a product aimed at researchers, the pharma industry The Readout June 30, 2026 STAT Plus: Investors double down on Bain-backed startup Subscriber Picks